tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

AMLX Stock Latest News

Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
RatingsCautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
1M ago
AMLX
Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market
PremiumRatings
Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market
1M ago
AMLX
Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation
PremiumCompany Announcements
Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation
1M ago
AMLX
Amylyx Pharmaceuticals Reports 2024 Financial Results
PremiumCompany Announcements
Amylyx Pharmaceuticals Reports 2024 Financial Results
1M ago
AMLX
Amylyx Pharmaceuticals’ Earnings Call Highlights Clinical Progress
PremiumCompany Announcements
Amylyx Pharmaceuticals’ Earnings Call Highlights Clinical Progress
1M ago
AMLX
Amylyx files $300M mixed securities shelf
PremiumThe FlyAmylyx files $300M mixed securities shelf
1M ago
AMLX
Amylyx reports Q4 EPS (55c) vs. 7c last year
Premium
The Fly
Amylyx reports Q4 EPS (55c) vs. 7c last year
1M ago
AMLX
AMLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AMLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
AMLX
Amylyx announces common stock offering, no amount given
PremiumThe Fly
Amylyx announces common stock offering, no amount given
3M ago
AMLX
Amylyx appoints Dan Monahan as Chief Commercial Officer
PremiumThe Fly
Amylyx appoints Dan Monahan as Chief Commercial Officer
3M ago
AMLX
Gubra and Amylyx team on novel long-acting GLP-1 receptor antagonist development
PremiumThe Fly
Gubra and Amylyx team on novel long-acting GLP-1 receptor antagonist development
3M ago
AMLX
Amylyx Partners with Gubra for GLP-1 Antagonist
PremiumCompany Announcements
Amylyx Partners with Gubra for GLP-1 Antagonist
3M ago
8K
AMLX
Amylyx announces design of LUCIDITY clinical trial
PremiumThe FlyAmylyx announces design of LUCIDITY clinical trial
4M ago
AMLX
Amylyx upgraded to Outperform from Neutral at Baird
Premium
The Fly
Amylyx upgraded to Outperform from Neutral at Baird
5M ago
AMLX
Amylyx price target raised to $12 from $8 at H.C. Wainwright
Premium
The Fly
Amylyx price target raised to $12 from $8 at H.C. Wainwright
5M ago
AMLX
Amylyx Pharmaceuticals Q3 2024 Financial Highlights
PremiumCompany Announcements
Amylyx Pharmaceuticals Q3 2024 Financial Highlights
5M ago
AMLX
Amylyx reports Q3 EPS ($1.07), consensus (71c)
PremiumThe Fly
Amylyx reports Q3 EPS ($1.07), consensus (71c)
5M ago
AMLX
Amylyx upgraded to Buy at BofA on ‘underappreciated’ PBH opportunity
PremiumThe Fly
Amylyx upgraded to Buy at BofA on ‘underappreciated’ PBH opportunity
6M ago
AMLX
Amylyx upgraded to Buy from Neutral at BofA
PremiumThe Fly
Amylyx upgraded to Buy from Neutral at BofA
6M ago
AMLX
Amylyx announces HELIOS clinical trial meets primary endpoint
PremiumThe FlyAmylyx announces HELIOS clinical trial meets primary endpoint
6M ago
AMLX
Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility
Premium
Company Announcements
Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility
6M ago
AMLX
Amylyx CFO buys $101.4K in common stock
Premium
The Fly
Amylyx CFO buys $101.4K in common stock
7M ago
AMLX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >